AIHTA - Publications - Search - Horizon Scanning in Oncology 40th Prioritisation – 3rd quarter 2019

Grössmann, N. and Rothschedl, E. and Wolf, S. (2019): Horizon Scanning in Oncology 40th Prioritisation – 3rd quarter 2019. HSO: 40th Prioritisation.

[thumbnail of HSO_40th_Prioritisation.pdf]
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader

For the 40th prioritisation (July 2019), eleven drugs were filtered out of 570 identified and were sent to prioritisation. Of these, 6 drugs were ranked as 'highly relevant' by the expert panel, 5 as 'relevant' and none as 'not relevant'. For 'highly relevant' drugs, further information including, for example, abstracts of phase III studies and licensing status is contained in this document.

Item Type:DSD: Horizon Scanning in Oncology
Subjects:WB Practice of medicine > WB 300-962 Therapeutics
QZ Pathology > QZ 200-380 Neoplasms.Cysts
QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
Series Name:HSO: 40th Prioritisation
Deposited on:29 Jul 2019 13:24
Last Modified:15 Jul 2020 17:59

Repository Staff Only: item control page